Pharmaceuticals occupiers in Bogotá typically cluster in Salitre & Connecta Business District, plan ~220 sqft per seat at high-end fit-out ($810000–1200000/sqft), and pay around 110000 COP/sqft ($31 USD) on Class A.
Pharmaceuticals occupiers in Bogotá typically cluster in Salitre & Connecta Business District, plan ~220 sqft per seat at high-end fit-out">fit-out ($810000–1200000/sqft), and pay around 110000 COP/sqft ($31 USD) on Class A.
Pharmaceuticals occupiers in Bogotá typically anchor in Salitre & Connecta Business District. Tech, BPO, multinational HQs, telecom.
Class A rent in Bogotá runs 110000 COP/sqft ($31 USD) on a 5-year lease with 5 months free. Prime submarkets sit at or modestly above the city index.
Typical pharmaceuticals fit-out targets high-end specification at $810000–1200000/sqft. Branded reception, full client-facing programming, premium furniture, and specialist AV are standard.
Plan around 220 sqft per seat blended (workstation + circulation + amenity). A 100-headcount pharma office in Bogotá typically targets 22,000 sqft of leasable area.
Commercial and medical-affairs teams cluster near academic-medical anchors; large floor plates support cross-functional brand teams. Deep banking, oil services, and BPO talent. Strong English fluency in international corporate. Strong feed from Universidad de los Andes, Universidad Nacional, Pontificia Javeriana.
Headline corporate tax: 35%. Net leases. 5-year terms with renewal options. Free rent of 3-6 months and TI of COP 350,000-700,000/sqm typical.
| city | Bogotá |
|---|---|
| industry | Pharmaceuticals |
| naics | 3254, 5417 |
| preferredSubmarket | Salitre & Connecta Business District |
| preferredFitoutSpec | High-end |
| fitoutBand | $810000–1200000/sqft |
| sqftPerSeat | 220 |
| classARentLocal | 110000 COP/sqft/yr |
| classARentUsd | $31/sqft/yr |
| vacancyPct | 14.6% |
| typicalLeaseYears | 5 |
| typicalRentFreeMonths | 5 |
| talentIndex | 76 |
| corporateTaxPct | 35% |
Reviewed by Miriam Hollander — Lead market analyst. Last updated 2026-04-15. See our methodology and editorial standards.